QTTB
Q32 Bio Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.05
−5.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
7.4x
Market Cap
$358.72M
MomentumView details →
1D Return
−5.86%
YTD Return
+261.75%
RSI (14)
29.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
7.4x
Market Cap
$358.72M
RSI (14)
29.2
MomentumView details →
1D Return
−5.86%
YTD Return
+261.75%
SummaryUpdated Jun 1, 2026
Q32 Bio Inc. (NASDAQ:QTTB) is a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. Originally incorporated as AdMIRx Inc., the company rebranded to Q32 Bio in April 2020 and went public in March 2018. The company focuses on developing innovative biologic therapeutics designed to restore healthy immune balance in patients suffering from autoimmune and inflammatory diseases caused by pathological immune dysfunction.
Similar companies
Latest newsMore news →
Q32 Bio Inc. reported its financial results for the second quarter of 2026, with cash and cash equivalents of $106.3 million as of June 30, 2026.30d agoQ32 Bio Inc. announced an underwritten public offering of $200 million of its common stock and pre-funded warrants.53d agoQ32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata, supporting further development and a planned registration-directed program in the first half of 2027.53d ago